Lixte Biotechnology Secures $1.05M for Cancer Trials

Introduction

LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT) is a clinical-stage pharmaceutical company headquartered in East Setauket, New York. The firm specializes in a class of oncology treatments known as PP2A inhibitors. Its lead molecule, LB-100, is being evaluated as an enhancer of both chemotherapy and immunotherapy for various cancer indications.

Corporate Structure and Experience

Lixte has a small team comprising between 2 and 10 employees, supported by a management team with extensive expertise in oncology and drug development.

• Bas van der Baan, CEO & President, has over 20 years of experience in precision oncology and clinical development.
• Jan Schellens, MD PhD, Chief Medical Officer, possesses more than 25 years of experience in oncology and pharmacology, with prior roles at the European Medicines Agency.
• Robert Weingarten, CFO & Vice President, holds a B.A. in Accounting and an M.B.A. in Finance, with over 30 years of experience in finance and compliance within public companies.

The board is composed of recognized leaders in clinical medicine and oncology, including Prof. René Bernards, Dr. Stephen Forman, and Dr. Yun Yen.

Oncology by National Cancer Institute

Developments and News

On February 11, 2025, Lixte announced a registered direct offering of 434,784 common shares at a purchase price of $2.415 per share, alongside a concurrent private placement of unregistered warrants exercisable at $2.29 per share for five years. The gross proceeds are expected to be approximately $1.05 million and will be allocated for working capital and general corporate purposes.

In June 2025, Lixte submitted a Form S-1 on June 18 and an amendment (S-1/A) on June 24 to register additional securities under the Securities Act of 1933, indicating preparations for future capital raises.

Current clinical trials include:

• A Phase 2 study in ovarian clear cell carcinoma (NCT06065462), combining LB-100 with dostarlimab.
• A Phase 1b trial in metastatic MSI Low colon cancer (NCT06012734), assessing LB-100 in conjunction with PD-1 blockade.
• A combined Phase I/II trial in advanced soft tissue sarcoma (NCT05809830), evaluating LB-100 with doxorubicin.

Financial and Strategic Analysis

Lixte’s February 2025 offering is projected to generate approximately $1.05 million before fees, which will assist in supporting ongoing trial enrollment and operational needs. The filings of Form S-1 and S-1/A in June provide a basis for future equity financings. The company’s strategy is centered on enhancing established cancer therapies—chemotherapy and immunotherapy—through PP2A inhibition, a novel mechanism that currently lacks direct competitors. A broad patent portfolio covering LB-100 and related molecules supports Lixte’s position in the oncology sector.

Market Position and Industry Context

As a clinical-stage biotechnology company, Lixte operates in the growing immuno-oncology field. The PP2A inhibitor approach targets a critical phosphatase involved in cell cycle regulation and DNA repair, aiming to address resistance and toxicity challenges associated with existing treatments. With LB-100 in multiple combination trials, Lixte is aligning with industry trends to develop adjunct therapies that may improve response rates and expand eligibility across various tumor types.

tl;dr

• February 11, 2025: Priced a registered direct offering of 434,784 shares at $2.415 and warrants at $2.29, expected to raise ~$1.05 million.
• June 18 & June 24, 2025: Filed Form S-1 and S-1/A in preparation for future equity offerings.
• Ongoing trials: Phase 2 in ovarian clear cell cancer (NCT06065462), Phase 1b in MSI Low colon cancer (NCT06012734), Phase I/II in soft tissue sarcoma (NCT05809830).
• As of July 1, 2025, shares closed at $1.3481, reflecting an increase of 48.96% on a trading volume of 1,848,139 shares.
• Upcoming catalysts include trial enrollment milestones, data readouts, and additional financings for working capital.